gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · TMDXHealthcareElectromedical Equipment

TransMedics Group, Inc. Common Stock (TMDX)

$74.13+10.08%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$74.13▼ 40.56% in range
Nov 3, 2025Low $62.04 · High $150.42Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

TransMedics Group closed at $74.13 on Nov 4, up 10.08%, 50.7% below its 52-week closing high. Volume of 809.1K shares was 0.93× its 20-day average (close to normal).

Split-adjusted performance: -7.7% over one month, +1.7% over six months, -40.6% over one year.

In the quarter ended Jun 30, 2026, revenue was $189.95M, up 20.7% from a year earlier, with a net margin of 7.7%.

Short interest was 8.8M shares at the Oct 15 settlement, up 2.5% from the prior report (27.3% of float, 9.9 days to cover).

Market cap$2.57B34.7M shares
Revenue · quarter$189.9M+20.7% YoY
Diluted EPS$0.41−55.4% YoY
P/E · TTM16.9×P/S 3.8×
Net margin7.7%Gross 59.6%
Dividend yieldNone
52-week range62.04 – 150.42−50.7% from high
Volume809.1K0.93× 20-day avg
Volatility · 60d46.9%Annualised
Short % of float27.3%9.9 days to cover
Net cash-$389.0MCash $472.7M
Next earnings—Not scheduled
Split-adjusted performance
1W +10.8%1M −7.7%3M −7.6%6M +1.7%YTD −39.1%1Y −40.6%3Y +101.8%5Y +178.7%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Electromedical Equipment

Percentile among 22 companies (100 = best)

6-month momentum57
Revenue growth59
Net margin84
Value (low P/E)—
Size81

Industry medians: 6-month return −0.8%, revenue growth +13.9%, net margin −44.6%, P/E 23.6×.

Short interest

Details →
Shares short8.8M+2.5% vs prior
Days to cover9.9Settled Oct 15
% of float27.3%
Short vol. 10d52.8%of daily volume

Closest peers by size in Electromedical Equipment

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
TMDXTransMedics Group$74.13+10.08%+1.7%+20.7%7.7%16.9$2.57B
AXGNAxogen$52.56+6.18%+20.9%+26.2%3.1%—$3.14BCompare
CNMDCONMED$53.09+12.40%+42.2%−0.7%5.9%21.5$1.58BCompare
ITGRInteger Holdings$126.73+0.14%+46.9%−3.9%3.3%41.5$4.31BCompare
LIVNLivaNova$99.01+23.92%+49.4%+10.8%27.8%28.9$5.46BCompare
CBLLCeriBell$27.65−2.19%+37.2%+29.9%−72.8%—$1.06BCompare
CVCapsoVision$6.99+4.33%−0.3%—−205.4%—$371.9MCompare
ELMDElectromed$28.03+4.90%+8.1%+11.6%17.5%20.6$232.3MCompare
STXSStereotaxis$0.9750+15.66%−49.2%−12.8%−62.3%—$97.7MCompare

News about TransMedics Group

All news →
TransMedics selects Gogo Galileo HDX for nationwide organ transport fleetGlobeNewswire Inc. · Oct 27, 2026▲ PositiveWhy Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?Zacks Investment Research · Sep 3, 2026▼ NegativeTransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDXGlobeNewswire Inc. · Sep 3, 2026▼ NegativeWhy TransMedics Stock Is Sinking TodayThe Motley Fool · Aug 5, 2026▲ PositiveWhere Will TransMedics Group Stock Be in 10 Years?The Motley Fool · Jul 3, 2026▲ Positive

Quick answers

What does TransMedics Group do?
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage.
What is TMDX's market cap?
$2.57B, based on the Nov 4 close of $74.13.
What is TMDX's P/E ratio?
16.9× trailing-twelve-month earnings of $151.70M.
Does TransMedics Group pay a dividend?
No regular cash dividend has been paid in the last year.
How much of TMDX is sold short?
8.8M shares, 27.3% of float, as of Oct 15, 2026.
What sector is TMDX in?
Healthcare, in the Electromedical Equipment industry.

About TransMedics Group

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

HQ: Andover, MA898 employeesListed May 2, 2019transmedics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology